BACKGROUND: PIK3CA mutations in the helical domain (in exon 9) and in the kinase domain (exon 20) cause tumor formation by different means. We aimed to determine the effects of each of these mutations on survival of colon carcinoma patients. METHODS: A large cohort of 685 colon carcinoma patients was tested for PIK3CA mutations in exons 9 and 20 by single nucleotide primer extension (N = 428) or by real time PCR (N = 257). RESULTS: PIK3CA mutation rate was 13%. 66 of 83 (79.5%) were in exon 9 and 17 of 83 (20.5%) in exon 20. In survival analysis, PIK3CA mutations in exon 9 and 20 had different effects on patient outcome. The PIK3CA exon 20 mutation conferred a poorer disease free survival compared to patients with wild type alleles and exon 9 mutations (Log rank p = 0.04 and p = 0.03 respectively) and cancer specific survival (Log rank p = 0.03 and p = 0.056 respectively) in stage III patients. In stage I and II this negative effect on outcome was not seen. CONCLUSIONS: PIK3CA mutation in exon 20 is a negative prognostic factor in stage III colon cancer patients. Moreover, this negative effect is not present in stage I and II patients.
BACKGROUND:PIK3CA mutations in the helical domain (in exon 9) and in the kinase domain (exon 20) cause tumor formation by different means. We aimed to determine the effects of each of these mutations on survival of colon carcinomapatients. METHODS: A large cohort of 685 colon carcinomapatients was tested for PIK3CA mutations in exons 9 and 20 by single nucleotide primer extension (N = 428) or by real time PCR (N = 257). RESULTS:PIK3CA mutation rate was 13%. 66 of 83 (79.5%) were in exon 9 and 17 of 83 (20.5%) in exon 20. In survival analysis, PIK3CA mutations in exon 9 and 20 had different effects on patient outcome. The PIK3CA exon 20 mutation conferred a poorer disease free survival compared to patients with wild type alleles and exon 9 mutations (Log rank p = 0.04 and p = 0.03 respectively) and cancer specific survival (Log rank p = 0.03 and p = 0.056 respectively) in stage III patients. In stage I and II this negative effect on outcome was not seen. CONCLUSIONS:PIK3CA mutation in exon 20 is a negative prognostic factor in stage III colon cancerpatients. Moreover, this negative effect is not present in stage I and II patients.
Authors: A Fariña-Sarasqueta; G van Lijnschoten; E Moerland; G-J Creemers; V E P P Lemmens; H J T Rutten; A J C van den Brule Journal: Ann Oncol Date: 2010-05-25 Impact factor: 32.976
Authors: Sara M Johnson; Pat Gulhati; Bill A Rampy; Yimei Han; Piotr G Rychahou; Hung Q Doan; Heidi L Weiss; B Mark Evers Journal: J Am Coll Surg Date: 2010-05 Impact factor: 6.113
Authors: Xiao-Ning Guo; Ashwani Rajput; Rebecca Rose; Jennie Hauser; Alexander Beko; Karen Kuropatwinski; Charles LeVea; Robert M Hoffman; Michael G Brattain; Jing Wang Journal: Cancer Res Date: 2007-06-15 Impact factor: 12.701
Authors: Arnaud D Roth; Sabine Tejpar; Mauro Delorenzi; Pu Yan; Roberto Fiocca; Dirk Klingbiel; Daniel Dietrich; Bart Biesmans; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Laura Cisar; Roberto Labianca; David Cunningham; Eric Van Cutsem; Fred Bosman Journal: J Clin Oncol Date: 2009-12-14 Impact factor: 44.544
Authors: Huan Pang; Rory Flinn; Antonia Patsialou; Jeffrey Wyckoff; Evanthia T Roussos; Haiyan Wu; Maria Pozzuto; Sumanta Goswami; John S Condeelis; Anne R Bresnick; Jeffrey E Segall; Jonathan M Backer Journal: Cancer Res Date: 2009-11-10 Impact factor: 12.701
Authors: Hans Prenen; Jef De Schutter; Bart Jacobs; Wendy De Roock; Bart Biesmans; Bart Claes; Diether Lambrechts; Eric Van Cutsem; Sabine Tejpar Journal: Clin Cancer Res Date: 2009-04-14 Impact factor: 12.531
Authors: F Jeroen Vogelaar; Felice N van Erning; Marlies S Reimers; Hans van der Linden; Hans Pruijt; Adriaan J C van den Brule; Koop Bosscha Journal: Mol Med Date: 2016-05-09 Impact factor: 6.354
Authors: Shuji Ogino; Xiaoyun Liao; Yu Imamura; Mai Yamauchi; Nadine J McCleary; Kimmie Ng; Donna Niedzwiecki; Leonard B Saltz; Robert J Mayer; Renaud Whittom; Alexander Hantel; Al B Benson; Rex B Mowat; Donna Spiegelman; Richard M Goldberg; Monica M Bertagnolli; Jeffrey A Meyerhardt; Charles S Fuchs Journal: J Natl Cancer Inst Date: 2013-11-14 Impact factor: 13.506
Authors: Patrick G Gavin; Linda H Colangelo; Debora Fumagalli; Noriko Tanaka; Matthew Y Remillard; Greg Yothers; Chungyeul Kim; Yusuke Taniyama; Seung Il Kim; Hyun Joo Choi; Nicole L Blackmon; Corey Lipchik; Nicholas J Petrelli; Michael J O'Connell; Norman Wolmark; Soonmyung Paik; Kay L Pogue-Geile Journal: Clin Cancer Res Date: 2012-10-08 Impact factor: 12.531
Authors: Xiaoyun Liao; Teppei Morikawa; Paul Lochhead; Yu Imamura; Aya Kuchiba; Mai Yamauchi; Katsuhiko Nosho; Zhi Rong Qian; Reiko Nishihara; Jeffrey A Meyerhardt; Charles S Fuchs; Shuji Ogino Journal: Clin Cancer Res Date: 2012-02-22 Impact factor: 12.531
Authors: Christophe Rosty; Joanne P Young; Michael D Walsh; Mark Clendenning; Kristy Sanderson; Rhiannon J Walters; Susan Parry; Mark A Jenkins; Aung Ko Win; Melissa C Southey; John L Hopper; Graham G Giles; Elizabeth J Williamson; Dallas R English; Daniel D Buchanan Journal: PLoS One Date: 2013-06-13 Impact factor: 3.240
Authors: V Eklöf; M L Wikberg; S Edin; A M Dahlin; B-A Jonsson; Å Öberg; J Rutegård; R Palmqvist Journal: Br J Cancer Date: 2013-05-09 Impact factor: 7.640